Chinese startup Enginprime Medical closes $12 M Series A financing

image credit- shutterstock

Enginprime Medical, a developer of percutaneous ventricular assist device (pVAD) technology, has announced the closing of a $12 million Series A financing round, exclusively led by Qiming Venture Partners. Proceeds will fund the registration clinical trial of OpusOne™ in China and support regulatory submissions and early-stage clinical development of the platform globally.

Founded in 2023 by Voyagers Capital and a team of experienced engineers, Enginprime is developing next-generation percutaneous ventricular assist systems. The company’s lead product, OpusOne™, is designed to deliver higher flow rates from a smaller catheter profile.

Zhiyong Liu, Chief Executive Officer of Enginprime said, “This funding marks a pivotal milestone as we advance and scale a globally competitive pVAD system. We are committed to executing our global clinical and regulatory strategies to deliver reliable, cost-effective percutaneous ventricular assist solutions to market.”

Shuo Mao, Principal of Qiming Venture Partners said, ” The foldable impeller pVAD achieves greater flow capacity with a lower-profile design, effectively reducing clinical complications and broadening patient eligibility and clinical applicability. It delivers significant clinical value for ventricular assist therapy. To date, no comparable product has obtained global regulatory approval, representing an untapped technological frontier in the industry.”